NSAIDs and the risk of CV events: is there a class effect?

By  

Inpharma, Vol. 1, Iss. 1492, 2005-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Reduced potential for hepatotoxicity with newer thiazolidinediones?

By  

Inpharma, Vol. 1, Iss. 1379, 2003-01 ,pp. : 19-20

Adis International

Access to resources Recommend Favorite

‘Sleep Attacks’ or ‘Unintended Sleep Episodes’ Occur with Dopamine Agonists: Is This a Class Effect?

By Chaudhuri K.R.  

Drug Safety, Vol. 25, Iss. 7, 2002-01 ,pp. : 473-483

Adis International

Access to resources Recommend Favorite

Intra-articular hyaluronan in OA: mostly placebo effect?

By  

Inpharma, Vol. 1, Iss. 1419, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Interferon-Beta in the Treatment of Multiple Sclerosis: Do Clinical Data Support the Existence of a Ceiling Effect?

By Clanet M.  

Clinical Drug Investigation, Vol. 21, Iss. 4, 2001-04 ,pp. : 307-318

Adis International

Access to resources Recommend Favorite